DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Modi S, Tsurutani J, Takahashi S. et al.
Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers.
Cancer Res 2018;
DOI: 10.1158/1538-7445.SABCS17-PD3-07.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.